Quarterly Updates5 Aug 2025, 04:52 pm
Gland Pharma Reports Revenue of ¥ 15,056 Mn for Q1FY26 with PAT up by 50% YoY; Cenexi Achieves EBITDA Breakeven
AI Summary
Gland Pharma Limited, a generic injectable-focused pharmaceutical company, has announced its financial results for the first quarter ended on 30th June 2025. The company reported a revenue of ¥ 15,056 Mn, with a 50% Year-over-Year (YoY) increase in Profit After Tax (PAT). Cenexi, a subsidiary of Gland Pharma, reported an EBITDA breakeven for the quarter. The company's strategic priorities are progressing, with a strong performance in the base business and a turnaround at Cenexi. Gland Pharma is strengthening its capabilities, adding new capacity, and boosting R&D with complex products and key partnerships.
Key Highlights
- Revenue increased by 7% YoY and 6% Quarter-on-Quarter (QoQ)
- EBITDA increased by 39% YoY and 6% QoQ
- EBITDA margin increased by 549 bps YoY to 24% in Q1FY26
- Adj. EBITDA increased by 41% YoY and 8% QoQ
- Adj. EBITDA margin increased by 589 bps YoY to 25% in Q1FY26
- PAT increased by 50% YoY and 16% QoQ
- PAT margin increased by 405 bps YoY to 14% in Q1FY26